Update on commercialisation of PromarkerD in the USA
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Groundbreaking results for type 1 diabetes and kidney health
- June 2024 Quarterly Activities Report and Appendix 4C
- Eurobio Scientific to sell PromarkerD DKD test in France
- Proteomics appoints medical devices sales agency for Europe
- March 2024 Quarterly Activities Report and Appendix 4C
Later from Proteomics International Laboratories
- Esophageal cancer diagnostic delivers excellent results
- September 2024 Quarterly Activities Report and Appendix 4C
- AGM Chairman's Address and Investor Presentation
- Proteomics receives $2.16 million in R&D tax incentive
- Breakthrough results for endometriosis diagnostic blood test
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories